Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2024-01-16 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
北京诺思兰德生物技术股份有限公司2023年度向特定对象发行股票发行情况报告书
Capital/Financing Update Classification · 100% confidence The document is titled "2023年度向特定对象发行股票发行情况报告书" which translates to "2023 Annual Report on Private Placement of Shares". It details the issuance of shares to specific investors, including the number of shares issued, pricing, subscription process, allocation, and the use of proceeds. It includes signatures from the board, supervisors, and senior management, and mentions regulatory approvals from the Beijing Stock Exchange and China Securities Regulatory Commission. The document is comprehensive and about a capital raising event through a private placement of shares. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. It is not an announcement of a report but the report itself, and it is not an annual report or earnings release. Therefore, the correct classification is CAP.
2024-01-16 Chinese
2023年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 third extraordinary shareholders' meeting of Beijing Northland Biotechnology Co., Ltd. It includes information about the meeting's time, place, attendance, voting results on various governance-related proposals, and legal opinions confirming the legality of the meeting and resolutions. The content focuses on shareholder meeting decisions, voting outcomes, and governance amendments, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full report like an annual or interim report, nor is it a presentation or a regulatory filing. It is also not a proxy solicitation or remuneration report. The length is about 4,000 characters, which is consistent with a detailed voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2023-12-14 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "Company Articles of Association" (公司章程) for Beijing Northland Biotech Co., Ltd., approved at the third extraordinary shareholders' meeting in 2023. It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, capital management, and other corporate governance matters. The content is a comprehensive set of internal rules and regulations governing the company’s organization and behavior, consistent with a governance document. It is not a financial report, earnings release, or announcement of voting results. It is not a proxy statement or remuneration report. The document is lengthy (15,000 characters) and contains substantive governance content. Therefore, it fits the category of Governance Information (CGR).
2023-12-14 Chinese
北京海润天睿律师事务所关于北京诺思兰德生物技术股份有限公司2023年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2023 third extraordinary shareholders' meeting of Beijing Nuosiland Biotechnology Co., Ltd. It details the legality and compliance of the meeting process, attendees, and voting results. The document is not a financial report, earnings release, or management discussion but rather a legal opinion related to a shareholders' meeting. It includes detailed voting results and confirms the legality of the meeting and resolutions passed. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of a shareholders' meeting. The document length is 4071 characters, which is sufficient to contain substantive content rather than a mere announcement or notice. Therefore, the appropriate classification is DVA with high confidence.
2023-12-14 Chinese
投资者关系活动记录表
Regulatory Filings Classification · 95% confidence The document is an investor relations activity record from Beijing Northland Biotech Co., Ltd. It details a recent investor meeting including participants, questions asked, and company responses. It also mentions a planned private placement (定增) with specifics on share issuance quantity. The document is not a financial report, earnings release, or regulatory filing but rather a record of investor relations activities and communication. It does not contain financial statements or audit information. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2023-12-10 Chinese
关于设立董事会审计委员会并选举委员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the establishment of a Board Audit Committee and the election of its members. It details the composition, responsibilities, and related governance rules of the committee. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management structural changes and governance practices. Therefore, it fits best under Board/Management Information (MANG) as it announces changes related to the company's board committees and management oversight structure.
2023-11-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.